

University of Massachusetts Medical School

eScholarship@UMMS

UMass Center for Clinical and Translational
Science Research Retreat

2012 UMass Center for Clinical and
Translational Science Research Retreat

May 22nd, 4:30 PM - 6:00 PM

The Iddm14 gene is Tcrbv-13S1A1: Prevention of Autoimmune Diabetes in the Rat with an Allele-Specific Depleting Antibody That Recognizes the V β 13a T Cell Receptor Beta Chain


Michael Habib

University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

 Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), [Immunology and Infectious Disease Commons](#), and the [Medical Immunology Commons](#)

Habib M, Eberwine R, Liu Z, Herrmann T, Greiner D, Cort L, Blankenhorn EP, Mordes JP. (2012). The Iddm14 gene is Tcrbv-13S1A1: Prevention of Autoimmune Diabetes in the Rat with an Allele-Specific Depleting Antibody That Recognizes the V β 13a T Cell Receptor Beta Chain. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2012/posters/29

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](#).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

THE *Iddm14* GENE IS *Tcrbv-13S1A1*: PREVENTION OF AUTOIMMUNE DIABETES IN THE RAT WITH AN ALLELE-SPECIFIC DEPLETING ANTIBODY THAT RECOGNIZES THE V β 13a T CELL RECEPTOR BETA CHAIN

Michael Habib, Ryan Eberwine, Zhijun Liu, Thomas Herrmann, Dale Greiner, Laura Cort, Elizabeth Blankenhorn and John P. Mordes

Worcester, MA, Würzburg, Germany, and Philadelphia, PA

Contact: Michael.habib@umassmed.edu

To identify new intervention strategies for autoimmune type 1 diabetes (T1D), we investigated several rat models of the disorder. We dissected the powerful *Iddm14* diabetes susceptibility locus in eight T1D susceptible vs. resistant rat strains by single nucleotide polymorphism (SNP) haplotyping. We identified an allele of a T cell receptor (TCR) beta chain gene, *Tcrb-V13S1A1* (encoding V13 β a) as a candidate gene. In three separate trials, treating LEW.1WR1 rats, which are susceptible to T1D, with a depleting anti-V β 13 monoclonal antibody reduced diabetes frequency from 75% (N=50) to 17% (N=30, p<0.001). Anti-V β 13 monoclonal antibody also prevented T1D in spontaneously diabetic BBDP rats. We then analyzed the phenotype of infiltrating T cells recovered from the cultured islets of LEW.1WR1 rats exposed to a diabetogenic trigger. Within 5 days, up to 22% of CD4⁺ T cells recovered from islets were V13 β +, most of these CD25⁺FoxP3⁻. We also recovered V β 13 transcripts from pre-diabetic islets and observed a limited number of J β variant transcripts, indicating an oligoclonal TCR response to pancreatic beta cells. These data indicate that, in susceptible rats, V13 β a on diabetogenic T cells is required to recognize a critical T1D autoantigen. Interestingly, the diabetogenic and non-diabetogenic alleles of V β 13 have non-conservative sequence differences in both CRR1 and CDR2. The data suggest that it is possible to prevent T1D in the rat with a very narrowly targeted deletional therapy. Preliminary data suggest that a specific alpha chain may preferentially pair with V β 13a. We are currently generating rat T cell hybridoma clones with which to analyze the interaction of putative autoantigens with a diabetogenic TCR.